Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12064445 Cytarabine conjugates for cancer therapy

Patent 12064445 was granted and assigned to Biosight Ltd. on August, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Stela Gengrinovitch0

Ruth Ben Yakar0

Date of Patent

August 20, 2024

0

Patent Application Number

173727400

Date Filed

July 12, 2021

0

Patent Citations

US Patent 8993278 Conjugates for cancer therapy and diagnosis

0

US Patent 7151092 Cytarabine monophosphate prodrugs

0

US Patent 7989188 Conjugates for cancer therapy and diagnosis

0

US Patent 8022279 Liposomal formulations of anthracycline agents and cytidine analogs

0

US Patent 9079958 CD33 binding agents

0

Patent Primary Examiner

Patrick T. Lewis

0

Patent abstract

The present invention relates to conjugates comprising cytarabine and an amino acid for use in the treatment of cancer. In particular, the present invention relates to conjugates of cytarabine and aspartic acid for use in the treatment of hematological cancers.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12064445 Cytarabine conjugates for cancer therapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.